|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/31/17 Ziopharm Oncology Inc 10-Q 6/30/17 53:3.8M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 615K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
11: R1 Document and Entity Information HTML 38K
12: R2 Balance Sheets HTML 98K
13: R3 Balance Sheets (Parenthetical) HTML 47K
14: R4 Statements of Operations HTML 48K
15: R5 Statements of Stockholders' Deficit HTML 60K
16: R6 Statements of Stockholders' Deficit HTML 18K
(Parenthetical)
17: R7 Statements of Cash Flows HTML 97K
18: R8 Statements of Cash Flows (Parenthetical) HTML 18K
19: R9 Business HTML 30K
20: R10 Financings HTML 20K
21: R11 Summary of Significant Accounting Policies HTML 27K
22: R12 Fair Value Measurements HTML 45K
23: R13 Net Loss per Share HTML 28K
24: R14 Commitments and Contingencies HTML 104K
25: R15 Related Party Transactions HTML 36K
26: R16 Stock-Based Compensation HTML 56K
27: R17 Preferred Stock HTML 34K
28: R18 Derivative Financial Instruments HTML 35K
29: R19 Summary of Significant Accounting Policies HTML 27K
(Policies)
30: R20 Fair Value Measurements (Tables) HTML 36K
31: R21 Net Loss per Share (Tables) HTML 25K
32: R22 Stock-Based Compensation (Tables) HTML 58K
33: R23 Derivative Financial Instruments (Tables) HTML 36K
34: R24 Business - Additional Information (Detail) HTML 21K
35: R25 Financings - Additional Information (Detail) HTML 25K
36: R26 Assets and Liabilities Measured at Fair Value on HTML 31K
Recurring Basis (Detail)
37: R27 Fair Value Measurements - Additional Information HTML 22K
(Detail)
38: R28 Potential Dilutive Shares Excluded from HTML 28K
Computation of Diluted Net Loss Per Share (Detail)
39: R29 Net Loss per Share - Additional Information HTML 26K
(Detail)
40: R30 Commitments and Contingencies - Additional HTML 303K
Information (Detail)
41: R31 Related Party Transactions - Additional HTML 115K
Information (Detail)
42: R32 Stock-Based Compensation Expense Included in HTML 25K
Statement of Operations (Detail)
43: R33 Stock-Based Compensation - Additional Information HTML 40K
(Detail)
44: R34 Fair Value of Stock Options Assumptions Using HTML 32K
Black-Scholes Option Valuation Model (Detail)
45: R35 Stock Option Activity Under Stock Option Plan HTML 62K
(Detail)
46: R36 Summary of Unvested Restricted Stock (Detail) HTML 42K
47: R37 Preferred Stock - Additional Information (Detail) HTML 54K
48: R38 Fair Values of Derivative Instruments to be HTML 23K
classified as Derivative Liabilities on Balance
Sheet (Detail)
49: R39 Change in Derivative Liability (Detail) HTML 25K
50: R40 Fair Value Assumptions Used in Probability HTML 29K
Weighted Approach and Monte Carlo Simulation Model
(Detail)
52: XML IDEA XML File -- Filing Summary XML 90K
51: EXCEL IDEA Workbook of Financial Reports XLSX 55K
5: EX-101.INS XBRL Instance -- ziop-20170630 XML 764K
7: EX-101.CAL XBRL Calculations -- ziop-20170630_cal XML 109K
8: EX-101.DEF XBRL Definitions -- ziop-20170630_def XML 487K
9: EX-101.LAB XBRL Labels -- ziop-20170630_lab XML 902K
10: EX-101.PRE XBRL Presentations -- ziop-20170630_pre XML 643K
6: EX-101.SCH XBRL Schema -- ziop-20170630 XSD 126K
53: ZIP XBRL Zipped Folder -- 0001193125-17-242331-xbrl Zip 110K
| EX-31.2 |
EXHIBIT 31.2
CERTIFICATION
I, Kevin G. Lafond, certify that:
1. I have reviewed this Form 10-Q of ZIOPHARM Oncology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: July 31, 2017
| /s/ Kevin G. Lafond |
| Senior Vice President - Finance, Chief Accounting Officer and Treasurer |
| (Principal Financial and Accounting Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 7/31/17 | 4, 8-K | ||
| For Period end: | 6/30/17 | 4 | ||
| List all Filings | ||||